Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Neoplasm Metastasis 1Cholangiocarcinoma 1

Interventions

pembrolizumab 244Nivolumab 140Cisplatin 135Cyclophosphamide 134Paclitaxel 113Carboplatin 108Gemcitabine 98Radiotherapy 83Dexamethasone 83Docetaxel 77atezolizumab 68Ipilimumab 68Doxorubicin 62Fluorouracil 60Blood Specimen Collection 58Bevacizumab 58fludarabine 54Rituximab 54Etoposide 53Oxaliplatin 52Surveys and Questionnaires 49Lenalidomide 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Cetuximab 44Capecitabine 44lenvatinib 43Radiosurgery 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × infigratinib × 1 year × Clear all
NCT04233567 2026-02-24

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
17 enrolled 12 charts
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT02657486 2026-02-09

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Memorial Sloan Kettering Cancer Center

Phase NA Completed
4 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡